Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Haemonetics ( (HAE) ).
On February 12, 2026, Haemonetics Corporation announced it had published its 2024-2025 Corporate Responsibility Report, making the document available through the corporate responsibility section of its website. The company characterized the report’s disclosure as furnished rather than filed under U.S. securities laws, signaling an effort to share environmental, social and governance information with stakeholders while limiting associated legal exposure.
The most recent analyst rating on (HAE) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.
Spark’s Take on HAE Stock
According to Spark, TipRanks’ AI Analyst, HAE is a Neutral.
The score is held back most by weak technicals (sharp downtrend and bearish momentum). Fundamentals are mixed: strong cash generation and profitability are offset by a steep TTM revenue decline and higher leverage. Valuation is reasonable at ~16x earnings, and the latest earnings call was supportive due to raised EPS/FCF guidance despite acknowledged segment headwinds.
To see Spark’s full report on HAE stock, click here.
More about Haemonetics
Haemonetics Corporation operates in the medical technology industry, specializing in blood management solutions and related products and services for healthcare systems, blood centers and hospitals. The company focuses on technologies that support blood and plasma collection, processing and transfusion, serving a global market that depends on high standards of quality, safety and regulatory compliance.
Average Trading Volume: 855,385
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.76B
For detailed information about HAE stock, go to TipRanks’ Stock Analysis page.